APA (7th ed.) Citation

Y, A., D, W., SS, W., J, K., & AR, K. (2025). Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy. Pediatric blood & cancer, 72(12), e32052. https://doi.org/10.1002/pbc.32052

Chicago Style (17th ed.) Citation

Y, Almodallal, Whitehurst D, Way SS, Koo J, and Kumar AR. "Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy." Pediatric Blood & Cancer 72, no. 12 (2025): e32052. https://doi.org/10.1002/pbc.32052.

MLA (9th ed.) Citation

Y, Almodallal, et al. "Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy." Pediatric Blood & Cancer, vol. 72, no. 12, 2025, p. e32052, https://doi.org/10.1002/pbc.32052.